Head and neck squamous cell carcinoma Trials in Philadelphia, United States
Conditions / Head and neck squamous cell carcinoma / Philadelphia, United States
Head and neck squamous cell carcinoma has been the subject of sustained clinical investigation across multiple research sites.
29 total trials for this combination
Showing top 10 of 29 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | RECRUITING | PHASE3 |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | TERMINATED | PHASE1/PHASE2 |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | RECRUITING | PHASE2 |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1 |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | RECRUITING | — |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | RECRUITING | — |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | RECRUITING | PHASE1 |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | RECRUITING | — |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | COMPLETED | PHASE2 |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 |